X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (134) 134
hiv infections - drug therapy (112) 112
female (106) 106
male (105) 105
adult (103) 103
index medicus (99) 99
infectious diseases (99) 99
middle aged (77) 77
immunology (62) 62
treatment outcome (58) 58
anti-hiv agents - therapeutic use (57) 57
hiv (55) 55
hiv infections - virology (55) 55
drug therapy (50) 50
tenofovir (49) 49
antiretroviral therapy (48) 48
drug therapy, combination (47) 47
viral load (45) 45
anti-hiv agents - administration & dosage (44) 44
adenine - analogs & derivatives (40) 40
rna, viral - blood (40) 40
anti-hiv agents - adverse effects (39) 39
human immunodeficiency virus--hiv (39) 39
safety (39) 39
aged (38) 38
double-blind method (38) 38
aids/hiv (37) 37
hiv infection (37) 37
virology (35) 35
antiretroviral drugs (34) 34
cd4 lymphocyte count (34) 34
emtricitabine (34) 34
hiv-1 - drug effects (34) 34
young adult (32) 32
antiviral agents (31) 31
dosage and administration (31) 31
pharmacology & pharmacy (31) 31
research (31) 31
hiv-1 (30) 30
lamivudine (29) 29
efficacy (28) 28
therapy (28) 28
adenine - therapeutic use (26) 26
drug administration schedule (26) 26
adenine - administration & dosage (25) 25
clinical trials (25) 25
efavirenz (25) 25
adolescent (24) 24
double-blind (24) 24
hiv infections - immunology (24) 24
hiv-1 - genetics (24) 24
health aspects (23) 23
deoxycytidine - analogs & derivatives (22) 22
drug combinations (22) 22
lamivudine - therapeutic use (21) 21
organophosphonates - administration & dosage (21) 21
protease inhibitors (21) 21
ritonavir (21) 21
abridged index medicus (20) 20
aids (20) 20
lamivudine - administration & dosage (20) 20
microbiology (20) 20
abacavir (19) 19
drug resistance, viral (19) 19
ritonavir - therapeutic use (19) 19
deoxycytidine - administration & dosage (18) 18
dideoxynucleosides - therapeutic use (18) 18
hiv-1 - isolation & purification (18) 18
hiv/aids (18) 18
medicine, general & internal (18) 18
pharmacokinetics (18) 18
ritonavir - administration & dosage (18) 18
care and treatment (17) 17
organophosphonates - therapeutic use (17) 17
adults (16) 16
atazanavir sulfate (16) 16
reverse transcriptase inhibitors - therapeutic use (16) 16
cobicistat (15) 15
comparative analysis (15) 15
dideoxynucleosides - administration & dosage (15) 15
hiv infections - blood (15) 15
raltegravir (15) 15
reverse transcriptase inhibitors - administration & dosage (15) 15
ribonucleic acid--rna (15) 15
adenine - adverse effects (14) 14
antiretroviral therapy, highly active - methods (14) 14
rna (14) 14
viruses (14) 14
combination (13) 13
deoxycytidine - therapeutic use (13) 13
lamivudine - adverse effects (13) 13
analysis (12) 12
anti-hiv agents (12) 12
anti-hiv agents - pharmacology (12) 12
carbamates - administration & dosage (12) 12
hiv protease inhibitors - administration & dosage (12) 12
infections (12) 12
organophosphonates - adverse effects (12) 12
raltegravir potassium (12) 12
reverse transcriptase inhibitors - adverse effects (12) 12
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1087 - 1097
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 1, pp. 43 - 52
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9692, pp. 796 - 806
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 6, pp. 803 - 813
Background. The MERIT (M̄araviroc versus Ēfavir̄enz īn T̄reatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in... 
HIV/AIDS | Tropisms | RNA | HIV | Stock options | Response rates | Viruses | Infections | Post hoc | HIV 1 | Virology | INFECTIOUS DISEASES | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | LOPINAVIR-RITONAVIR | THERAPY | VIROLOGICAL FAILURE | RESISTANT HIV-1 | INHIBITOR | CORECEPTOR TROPISM | PLUS | Anti-HIV Agents - pharmacology | Lamivudine - administration & dosage | Cyclohexanes - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | Anti-HIV Agents - standards | Viral Load | Zidovudine - administration & dosage | Young Adult | Cyclohexanes - therapeutic use | Receptors, CCR5 - metabolism | HIV-1 - physiology | Adult | Female | Triazoles - standards | Viral Tropism | Drug Therapy, Combination | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Antiviral Agents - pharmacology | Double-Blind Method | HIV-1 - drug effects | Treatment Outcome | Anti-Retroviral Agents | Benzoxazines - standards | Benzoxazines - therapeutic use | Triazoles - pharmacology | Adolescent | Benzoxazines - pharmacology | Cyclohexanes - standards | HIV Infections - drug therapy | Aged | Drug Combinations | Maraviroc | Patient outcomes | Physiological aspects | Dosage and administration | Genetic aspects | Research | Drug therapy, Combination | Drug therapy | HIV infection | Efavirenz | Chemokines
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 396 - 407
Journal Article